The FDA on November 13, 2025, approved POHERDY® as an interchangeable biosimilar to PERJETA® (Pertuzumab). This is the first approval of a biosimilar for PERJETA®. POHERDY® is a product of Shanghai Henlius Biologics Co. Ltd. and PERJETA® is a product of Genentech Inc.
Bottom Ad
Advertisement
Subscribe
